Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 2,586 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 2,586 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the sale, the insider now owns 44,746 shares in the company, valued at $581,250.54. This represents a 5.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Friday, December 6th, Barry Ticho sold 13,945 shares of Stoke Therapeutics stock. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10.
• On Monday, December 2nd, Barry Ticho sold 10,000 shares of Stoke Therapeutics stock. The shares were sold at an average price of $12.07, for a total value of $120,700.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $12.98 on Thursday. Stoke Therapeutics, Inc. has a 1 year low of $4.09 and a 1 year high of $17.58. The firm has a market capitalization of $687.55 million, a PE ratio of -6.18 and a beta of 0.95. The business’s 50 day moving average price is $12.48 and its 200-day moving average price is $13.67.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. As a group, analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently modified their holdings of STOK. Price T Rowe Associates Inc. MD boosted its holdings in Stoke Therapeutics by 5.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock valued at $425,000 after purchasing an additional 1,642 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Stoke Therapeutics by 610.3% in the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock valued at $927,000 after acquiring an additional 58,943 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Stoke Therapeutics in the second quarter worth approximately $19,835,000. Nisa Investment Advisors LLC increased its stake in Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Stoke Therapeutics by 28.9% in the second quarter. Bank of New York Mellon Corp now owns 115,892 shares of the company’s stock valued at $1,566,000 after purchasing an additional 25,988 shares during the period.

Wall Street Analysts Forecast Growth

STOK has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.